Search Results for: covid-19
Articles
IMUNON Finalizes Phase 3 Study Design With FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer March 24, 2025
IMUNON, Inc. recently announced the US FDA is aligned with the protocol for the Phase 3 pivotal trial, called OVATION...Traws Pharma’s Bird Flu Drug Candidate Presented at ICAR March 21, 2025
Traws Pharma, Inc. recently announced that positive data supporting the potential for tivoxavir marboxil (TXM) as a bird flu treatment...Curevo Raises $110 Million to Advance Amezosvatein Shingles Vaccine March 18, 2025
Curevo Vaccine recently announced the closing of a $110-million Series B round to advance development of amezosvatein, its vaccine for...IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer February 19, 2025
IMUNON, Inc. recently announced new translational data from ongoing analyses of results from the Company’s Phase 2 OVATION 2 Study of...SPECIAL FEATURE - Analytical Testing – Diverse Demands & Therapies Require Diverse Analyses February 11, 2025
Contributor Cindy H. Dubin highlights how analytical testing has evolved to address diverse pharmaceutical therapeutics in research and development.
LEADERSHIP PANEL - What Will Have the Most Impact on Drug Development in 2025? February 11, 2025
Contributor Cindy H. Dubin asked several life science leaders what they believe will have the greatest impact on drug development in 2025.
VACCINE DEVELOPMENT - Enhancing Pandemic Preparedness With Mosaic-8b Nanoparticles February 10, 2025
Leonardo Magneschi, PhD, says although the mosaic-8b vaccine is still in early development, it has the potential to enable a broad and cross-reactive immunization strategy that could provide comprehensive protection against known and unknown sarbecoviruses.
Abzena Strengthens Board With Appointment of Biopharma Industry Leader, Dr. Moncef Slaoui January 14, 2025
Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, has today announced the appointment of Moncef...Invivyd Announces Continued Neutralizing Activity of PEMGARDA Against Dominant SARS-CoV-2 Variant XEC January 10, 2025
Invivyd, Inc. recently announced new in vitro neutralization data show continued neutralizing activity of PEMGARDA (pemivibart) and pipeline candidate VYD2311...Abzena Strengthens Board With Appointment of Biopharma Industry Leader January 8, 2025
Abzena recently announced the appointment of Moncef Slaoui, PhD, to its Board of Directors. A highly accomplished leader in the...IMUNON Announces Positive CMC Meeting With FDA for Advanced Ovarian Cancer Treatment December 19, 2024
IMUNON, Inc. recently announced the positive outcome of a Type C Chemistry, Manufacturing, and Controls (CMC) meeting with the US...EXECUTVE INTERVIEW - Aptar: Advancing Patient-Centric Drug Delivery & Digital Health Solutions December 10, 2024
Gael Touya, President of Aptar Pharma, and Sai Shankar, President, M&A, Strategy, BD, Marketing, Drug Services, Aptar Pharma, discuss the burgeoning potential in the future of pharma and digital health, how the company is a strategic partner to key players in these spaces, and the investments Aptar is making to support the growing demand.
IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001 December 10, 2024
IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced additional clinical data from ongoing...IMUNON Announces Results From its End-of-Phase 2 Meeting With the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer November 25, 2024
IMUNON, Inc. recently announced the outcome of its recent End-of-Phase 2 in-person meeting with the US FDA, supporting the advancement...HCW Biologics & WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate November 18, 2024
HCW Biologics Inc. and WY Biotech Co., Ltd. recently announced they have entered into a worldwide exclusive license agreement to...Naobios & Sumagen Successfully Optimize HIV Vaccine Candidate for Industrial Production October 29, 2024
Naobios and Sumagen Canada Inc. recently announced the production of the HIV-1 vaccine candidate at bench scale. This key milestone...mRNA Licensing Agreements Surge 800% in Value as Confidence Grows Beyond Vaccines October 16, 2024
Messenger ribonucleic acid (mRNA)-based innovator pharmaceuticals saw a staggering 800% increase in licensing agreement deal values from 2019 to 2024YTD,...Sterling Pharma Solutions Announces Partnership With Soligenix October 3, 2024
Sterling Pharma Solutions and Soligenix recently announced a partnership that will see Sterling manufacture a GMP-quality synthetic hypericin developed by...FORMULATION FORUM - Lyophilization Technology - An Enabler for Stable Formulations of Small & Large Molecules October 2, 2024
Shaukat Ali, PhD, and Jim Huang, PhD, explain how lyophilization or freeze-drying technology is one of the ideal methods that leads to immobilization of drug and other components that remain in solid or powder state for extended periods without concerns of degradation, and how it has also been applied to improve drug solubility by means of amorphous solid dispersions.
EXECUTIVE INTERVIEW - Respiratory Drug Development: Lonza Experts Share Trends & Key Takeaways October 1, 2024
Beatriz Fernandes, Principal Scientist for R&D, and Kim Shepard, Director, Technology Head Respiratory Delivery, at Lonza, discuss their presentations at RDD 2024, current trends, and the future of the inhalation space.
